HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[High-dose cepharanthin therapy of idiopathic thrombocytopenic purpura].

Abstract
Clinical efficacy of oral high-dose cepharanthin (40-60 mg/day) was evaluated in nine patients with idiopathic thrombocytopenic purpura who were unable to discontinue the administration of adrenocorticosteroids or immunosuppressive drugs. Mean platelet counts significantly (p less than 0.05) rose from 4.5 +/- 0.9 x 10(4)/microliters to 8.9 +/- 4.2 x 10(4)/microliters without any side effects. Two to five months after the initiation of this therapy, 4 patients, including 3 who could discontinue adrenocorticosteroids, kept their platelet counts over 10 x 10(4)/microliters. It was suggested that the oral administration of cepharanthin could be a beneficial and safe strategy for ITP.
AuthorsM Kobayashi, T Katayama, S Ochiai, M Yoshida, K Kaito, H Masuoka, T Shimada, K Nishiwaki, O Sakai
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 33 Issue 3 Pg. 405-7 (Mar 1992) ISSN: 0485-1439 [Print] Japan
PMID1578648 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Alkaloids
  • Benzylisoquinolines
  • cepharanthine
Topics
  • Administration, Oral
  • Adult
  • Alkaloids (administration & dosage, pharmacology)
  • Benzylisoquinolines
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Count (drug effects)
  • Purpura, Thrombocytopenic (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: